Elec AD, Oltean M, Goldis P, et al. - Given the lack of effective COVID-19 treatments, repurposing of several drugs, including antiretrovirals (ARV) and remdesivir (RDV), is mandatory. In patients with poor renal function, such as kidney transplant recipients (KTx), these compounds may instigate acute kidney injuries and are not recommended. Of 42 KTx with COVID-19, some were receiving ARV (n = 10) or RDV (n = 8) as part of the COVID-19 management. Death during hospitalization was reported for seven patients (16.6%). Twenty-four percent KTx had acute kidney injury at admission. Upon discharge, an increase in eGFR occurred in 32% and its decrease occurred in 39% of the KTx compared with the admission. Return to baseline eGFR values was reported among most patients (62%) within 1 month from discharge. Overall findings suggest that risk of COVID-19-related renal impairment was high in KTx. Use of antivirals seems safe without major risks for kidney injury.